$QURE
uniQure N.V.

2022 Q3 Form 10-Q Financial Statement

#000155837022012523 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $1.449M $497.0K $1.792M
YoY Change -27.15% -99.89% 294.71%
Cost Of Revenue $861.0K $832.0K
YoY Change -96.41%
Gross Profit $588.0K -$335.0K
YoY Change -70.44% -100.08%
Gross Profit Margin 40.58% -67.4%
Selling, General & Admin $13.32M $12.49M $10.99M
YoY Change 10.82% -27.79% -11.22%
% of Gross Profit 2265.99%
Research & Development $48.07M $46.19M $45.00M
YoY Change 31.94% 41.06% 37.81%
% of Gross Profit 8174.83%
Depreciation & Amortization $2.103M $1.981M $2.122M
YoY Change 18.15% 9.63% 14.09%
% of Gross Profit 357.65%
Operating Expenses $61.39M $58.68M $55.99M
YoY Change 26.7% 17.26% 24.34%
Operating Profit -$59.52M -$56.06M -$54.08M
YoY Change 32.26% -114.09% 21.64%
Interest Expense $3.069M $2.694M $2.515M
YoY Change 59.51% 41.64% 62.15%
% of Operating Profit
Other Income/Expense, Net $199.0K $229.0K $193.0K
YoY Change -7.01% 1.33% -17.17%
Pretax Income -$48.19M -$39.38M -$47.29M
YoY Change 32.23% -109.78% 14.39%
Income Tax -$329.0K -$318.0K -$616.0K
% Of Pretax Income
Net Earnings -$47.86M -$39.06M -$46.68M
YoY Change 31.0% -109.78% 12.33%
Net Earnings / Revenue -3302.76% -7859.36% -2604.8%
Basic Earnings Per Share -$1.02 -$0.84 -$1.00
Diluted Earnings Per Share -$1.02 -$0.84 -$1.00
COMMON SHARES
Basic Shares Outstanding 46.73M 46.67M 46.60M
Diluted Shares Outstanding 46.77M 46.67M 46.60M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $440.3M $500.5M $524.9M
YoY Change -23.88% -26.1% 101.26%
Cash & Equivalents $440.3M $500.5M $524.9M
Short-Term Investments
Other Short-Term Assets $16.59M $16.71M $14.68M
YoY Change 43.86% 17.75% 113.22%
Inventory $4.075M $2.949M
Prepaid Expenses $13.69M $15.13M $12.42M
Receivables $3.603M $3.119M $38.64M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $464.6M $523.3M $578.2M
YoY Change -21.76% -24.62% 104.8%
LONG-TERM ASSETS
Property, Plant & Equipment $47.89M $45.98M $44.92M
YoY Change 16.19% 19.84% 32.65%
Goodwill $23.42M $24.98M $26.57M
YoY Change -16.54% 4657.33% 5028.38%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.085M $5.974M $5.937M
YoY Change 7.36% 3.72% -68.59%
Total Long-Term Assets $173.7M $177.9M $178.9M
YoY Change -3.98% 97.59% 119.49%
TOTAL ASSETS
Total Short-Term Assets $464.6M $523.3M $578.2M
Total Long-Term Assets $173.7M $177.9M $178.9M
Total Assets $638.2M $701.2M $757.2M
YoY Change -17.61% -10.59% 108.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.566M $10.03M $9.920M
YoY Change 40.82% -40.37% 72.55%
Accrued Expenses $26.44M $23.05M $19.95M
YoY Change -14.01% -2.04% -4.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $63.97M $48.26M $44.70M
YoY Change 52.62% 4.7% 39.24%
LONG-TERM LIABILITIES
Long-Term Debt $102.4M $101.9M $101.4M
YoY Change 43.23% 43.95% 43.93%
Other Long-Term Liabilities $3.053M $3.493M $3.439M
YoY Change -19.83% 7.58% 10.69%
Total Long-Term Liabilities $153.1M $166.5M $166.4M
YoY Change 7.85% 59.2% 61.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $63.97M $48.26M $44.70M
Total Long-Term Liabilities $153.1M $166.5M $166.4M
Total Liabilities $217.1M $214.7M $211.1M
YoY Change 18.05% 42.53% 56.22%
SHAREHOLDERS EQUITY
Retained Earnings -$588.7M -$540.9M -$501.8M
YoY Change 27.06% 26.72% -39.27%
Common Stock $2.830M $2.823M $2.821M
YoY Change 1.18% 1.26% 1.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $421.2M $486.5M $546.0M
YoY Change
Total Liabilities & Shareholders Equity $638.2M $701.2M $757.2M
YoY Change -17.61% -10.59% 108.09%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$47.86M -$39.06M -$46.68M
YoY Change 31.0% -109.78% 12.33%
Depreciation, Depletion And Amortization $2.103M $1.981M $2.122M
YoY Change 18.15% 9.63% 14.09%
Cash From Operating Activities -$48.99M -$15.68M -$25.71M
YoY Change 22.0% -103.76% -37.71%
INVESTING ACTIVITIES
Capital Expenditures -$3.985M -$4.579M $4.058M
YoY Change -48.21% 98.14% 4.7%
Acquisitions $822.0K
YoY Change
Other Investing Activities -$1.078M $0.00 -$822.0K
YoY Change -97.84%
Cash From Investing Activities -$5.063M -$4.579M -$4.880M
YoY Change -91.22% 98.14% 25.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 301.0K 58.00K 485.0K
YoY Change -283.54% -97.69% -99.23%
NET CHANGE
Cash From Operating Activities -48.99M -15.68M -25.71M
Cash From Investing Activities -5.063M -4.579M -4.880M
Cash From Financing Activities 301.0K 58.00K 485.0K
Net Change In Cash -53.75M -20.20M -31.27M
YoY Change -45.13% -104.85% -297.32%
FREE CASH FLOW
Cash From Operating Activities -$48.99M -$15.68M -$25.71M
Capital Expenditures -$3.985M -$4.579M $4.058M
Free Cash Flow -$45.01M -$11.10M -$29.77M
YoY Change 38.64% -102.65% -34.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
3488000
dei Trading Symbol
TradingSymbol
QURE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Amendment Flag
AmendmentFlag
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46729077
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
500524000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
556256000
CY2022Q2 qure Accounts Receivable And Contract With Customer Asset Current
AccountsReceivableAndContractWithCustomerAssetCurrent
3119000
CY2021Q4 qure Accounts Receivable And Contract With Customer Asset Current
AccountsReceivableAndContractWithCustomerAssetCurrent
58768000
CY2022Q2 us-gaap Inventory Net
InventoryNet
2949000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15126000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10540000
CY2022Q2 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
1581000
CY2021Q4 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
2675000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
523299000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
628239000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
39400000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36900000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
45984000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14682000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43505000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28482000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25573000
dei Document Transition Report
DocumentTransitionReport
false
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
57450000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
62686000
CY2022Q2 us-gaap Goodwill
Goodwill
24976000
CY2021Q4 us-gaap Goodwill
Goodwill
27633000
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
15046000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
15647000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5974000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5897000
CY2022Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
177912000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
90000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
180941000
CY2022Q2 us-gaap Assets
Assets
701211000
CY2021Q4 us-gaap Assets
Assets
809180000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
10028000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2502000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23047000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28487000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8681000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6505000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5774000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
48261000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36763000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
101890000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
100963000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
20405000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
29542000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30721000
us-gaap Interest Paid Net
InterestPaidNet
2943000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28987000
CY2022Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
9953000
qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
-277000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12913000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3493000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4236000
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
166462000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
176641000
CY2022Q2 us-gaap Liabilities
Liabilities
214723000
CY2021Q4 us-gaap Liabilities
Liabilities
213404000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46684583
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46298635
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
2823000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2802000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1092176000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1076972000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-67630000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-28856000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-540881000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-455142000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
486488000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
595776000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
701211000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
809180000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
497000
dei Entity File Number
EntityFileNumber
001-36294
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
463868000
dei Entity Registrant Name
EntityRegistrantName
uniQure N.V.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2289000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
464322000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23178000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23178000
CY2022Q2 us-gaap Manufacturing Costs
ManufacturingCosts
832000
us-gaap Manufacturing Costs
ManufacturingCosts
832000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46192000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32747000
dei Entity Address Address Line1
EntityAddressAddressLine1
Paasheuvelweg 25
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
1105 BP
dei Entity Address City Or Town
EntityAddressCityOrTown
Amsterdam
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91195000
dei Entity Address Country
EntityAddressCountry
NL
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64777000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-14502000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Security12b Title
Security12bTitle
Ordinary Shares, par value €0.05
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46684583
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46298635
dei Entity Central Index Key
EntityCentralIndexKey
0001590560
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei City Area Code
CityAreaCode
31
dei Local Phone Number
LocalPhoneNumber
20-240-6000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12491000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17299000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
23478000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30300000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
59515000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
73224000
us-gaap Costs And Expenses
CostsAndExpenses
115505000
us-gaap Costs And Expenses
CostsAndExpenses
118255000
CY2022Q2 us-gaap Other Income
OtherIncome
3186000
CY2021Q2 us-gaap Other Income
OtherIncome
7590000
us-gaap Other Income
OtherIncome
3496000
us-gaap Other Income
OtherIncome
7942000
CY2022Q2 us-gaap Other Expenses
OtherExpenses
229000
CY2021Q2 us-gaap Other Expenses
OtherExpenses
226000
us-gaap Other Expenses
OtherExpenses
422000
us-gaap Other Expenses
OtherExpenses
459000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-56061000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
398008000
us-gaap Operating Income Loss
OperatingIncomeLoss
-110142000
us-gaap Operating Income Loss
OperatingIncomeLoss
353550000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
35000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
37000
us-gaap Investment Income Interest
InvestmentIncomeInterest
78000
us-gaap Investment Income Interest
InvestmentIncomeInterest
77000
CY2022Q2 us-gaap Interest Expense
InterestExpense
2694000
CY2021Q2 us-gaap Interest Expense
InterestExpense
1902000
us-gaap Interest Expense
InterestExpense
5210000
us-gaap Interest Expense
InterestExpense
3453000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
19398000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6583000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
27966000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
11209000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-57000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
635000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39379000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
402726000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-86673000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
361383000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-318000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3258000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-934000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3471000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39061000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
399468000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85739000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
357912000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-28324000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-6942000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-38774000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-67385000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
392526000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-124513000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
343410000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.82
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.67
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46668554
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46037900
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46634026
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45754766
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46668554
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46929870
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46634026
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46678835
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
228690000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
399468000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-6942000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1865000
CY2021Q2 qure Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Tax Effect Prior Years
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
2977000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
519000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7031000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
633608000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
546001000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39061000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-28324000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7813000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
30000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
486488000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
243905000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
357912000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14502000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29564000
qure Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Tax Effect Prior Years
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
2977000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
911000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12792000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
49000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
633608000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
595776000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85739000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-38774000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
453000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
486488000
us-gaap Profit Loss
ProfitLoss
-85739000
us-gaap Profit Loss
ProfitLoss
357912000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4103000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3667000
us-gaap Share Based Compensation
ShareBasedCompensation
14682000
us-gaap Share Based Compensation
ShareBasedCompensation
12792000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-934000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
3471000
qure Change In Fair Value Of Derivative Financial Instruments And Contingent Consideration
ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration
1371000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
24491000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
12279000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
257000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2932000
qure Increase Decrease In Accounts Receivable And Contract Assets Prepaid Expenses And Other Current Assets And Receivables
IncreaseDecreaseInAccountsReceivableAndContractAssetsPrepaidExpensesAndOtherCurrentAssetsAndReceivables
-46492000
qure Increase Decrease In Accounts Receivable And Contract Assets Prepaid Expenses And Other Current Assets And Receivables
IncreaseDecreaseInAccountsReceivableAndContractAssetsPrepaidExpensesAndOtherCurrentAssetsAndReceivables
3355000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2949000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7632000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10444000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1299000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5486000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41389000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
375206000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8637000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6191000
qure Payments To Acquire Remaining Outstanding Ordinary Shares
PaymentsToAcquireRemainingOutstandingOrdinaryShares
822000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9459000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6191000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
543000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
960000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
34603000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30899000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1334000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
543000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65128000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5382000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1665000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-55687000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
432478000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
559353000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247680000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
503666000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
680158000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
500524000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
677330000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3142000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2828000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
503666000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
680158000
us-gaap Interest Paid Net
InterestPaidNet
3980000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1</b></span>General business information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">uniQure (the “Company”) was incorporated on January 9, 2012 as a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company’s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics (AMT) Holding N.V (“AMT”). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability (<i style="font-style:italic;">naamloze vennootschap</i>) and changed its legal name from uniQure B.V. to uniQure N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 1pt 0pt 1pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is registered in the trade register of the Chamber of Commerce (<i style="font-style:italic;">Kamer van Koophandel</i>) in Amsterdam, the Netherlands under number 54385229. The Company’s headquarters are in Amsterdam, the Netherlands, and its registered office is located at Paasheuvelweg 25, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol “QURE”.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.3</b></span><span style="display:inline-block;width:18pt;"/><b style="font-weight:bold;">Use of estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2022Q2 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
15195000
CY2021Q4 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
13012000
CY2020Q4 qure Number Of Collaboration Targets
NumberOfCollaborationTargets
4
CY2020Q4 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2020Q4 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2020Q4 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8700000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
29100000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7852000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12603000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2872000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23047000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28487000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
11900000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
500000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46634026
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46678835
CY2021Q3 us-gaap Deferred Compensation Arrangement With Individual Requisite Service Period1
DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
P1Y
CY2021Q4 us-gaap Deferred Compensation Arrangement With Individual Requisite Service Period1
DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
P3Y
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.008
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.258
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.258
CY2021Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.008
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.010
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39061000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
399468000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85739000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
357912000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39061000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
399468000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85739000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
357912000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46668554
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46037900
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46634026
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45754766
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46668554
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46929870
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6869508
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3393724
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6869508
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3361343

Files In Submission

Name View Source Status
qure-20220630x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
qure-20220630_cal.xml Edgar Link unprocessable
qure-20220630_def.xml Edgar Link unprocessable
0001558370-22-012523-index-headers.html Edgar Link pending
0001558370-22-012523-index.html Edgar Link pending
0001558370-22-012523.txt Edgar Link pending
0001558370-22-012523-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
qure-20220630.xsd Edgar Link pending
qure-20220630x10q.htm Edgar Link pending
qure-20220630xex31d1.htm Edgar Link pending
qure-20220630xex31d2.htm Edgar Link pending
qure-20220630xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
qure-20220630_lab.xml Edgar Link unprocessable
qure-20220630_pre.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending